norbuprenorphine has been researched along with Delayed Effects, Prenatal Exposure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alund, AW; Brents, LK; Cabanlong, CV; Caperton, CO; Fantegrossi, WE; Griffin, BA; Martins, BS; Moran, JH; Owens, SM; Patton, AL; Russell, LN; Urquhart, KR; Wilson, CD; Zita, MD | 1 |
| Bartu, AE; Doherty, DA; Gower, S; Hackett, LP; Hamilton, D; Ilett, KF | 1 |
2 other study(ies) available for norbuprenorphine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.
Topics: Animals; Animals, Newborn; Buprenorphine; Female; Fetus; Opioid-Related Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Risk; Substance Withdrawal Syndrome | 2019 |
Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment.
Topics: Adult; Analgesics, Opioid; Apgar Score; Australia; Breast Feeding; Buprenorphine; Chromatography, Liquid; Female; Humans; Infant Welfare; Infant, Newborn; Male; Mass Spectrometry; Milk, Human; Opiate Substitution Treatment; Pregnancy; Prenatal Exposure Delayed Effects; Surveys and Questionnaires; Treatment Outcome | 2012 |